Old Web
English
Sign In
Acemap
>
authorDetail
>
J. Viscusi
J. Viscusi
Carboplatin
Pharmacodynamics
Cisplatin
Gemcitabine
Pharmacology
3
Papers
64
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
2011
Journal of Clinical Oncology
Jan H. M. Schellens
Geoffrey I. Shapiro
Anna C. Pavlick
Raoul Tibes
Suzanne Leijen
Sara M. Tolaney
I. Diaz Padilla
Ramesh K. Ramanathan
Tim Demuth
J. Viscusi
Jonathan D. Cheng
Raymond Lam
Y. Xu
Amit M. Oza
Show All
Source
Cite
Save
Citations (13)
A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
2010
Journal of Clinical Oncology
Suzanne Leijen
Jan H. M. Schellens
Geoffrey I. Shapiro
Anna C. Pavlick
Raoul Tibes
Tim Demuth
J. Viscusi
Jonathan D. Cheng
Y. Xu
Amit M. Oza
Show All
Source
Cite
Save
Citations (35)
A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors
2009
Journal of Clinical Oncology
Jan H. M. Schellens
Suzanne Leijen
Geoffrey I. Shapiro
Anna C. Pavlick
Raoul Tibes
S. J. ODay
Tim Demuth
J. Viscusi
Y. Xu
Amit M. Oza
Show All
Source
Cite
Save
Citations (16)
1